FR2869904A1 - Modulateurs des recepteurs lxr - Google Patents

Modulateurs des recepteurs lxr

Info

Publication number
FR2869904A1
FR2869904A1 FR0404958A FR0404958A FR2869904A1 FR 2869904 A1 FR2869904 A1 FR 2869904A1 FR 0404958 A FR0404958 A FR 0404958A FR 0404958 A FR0404958 A FR 0404958A FR 2869904 A1 FR2869904 A1 FR 2869904A1
Authority
FR
France
Prior art keywords
lxr
relates
receiver modulators
modulators
receiver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0404958A
Other languages
English (en)
Other versions
FR2869904B1 (fr
Inventor
Luc Lebreton
Christine Massardier
Christine Dumas
Pierre Dodey
Philippe Masson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0404958A priority Critical patent/FR2869904B1/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to JP2007512270A priority patent/JP4892475B2/ja
Priority to PCT/FR2005/001139 priority patent/WO2005121093A1/fr
Priority to CA002564642A priority patent/CA2564642A1/fr
Priority to AU2005251979A priority patent/AU2005251979B2/en
Priority to EP05769960A priority patent/EP1742918A1/fr
Priority to CN2011102511968A priority patent/CN102321020A/zh
Priority to CNA2005800146178A priority patent/CN1950340A/zh
Publication of FR2869904A1 publication Critical patent/FR2869904A1/fr
Application granted granted Critical
Publication of FR2869904B1 publication Critical patent/FR2869904B1/fr
Priority to US11/593,474 priority patent/US7872021B2/en
Priority to NO20065501A priority patent/NO20065501L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés dérivés de benzènesulfonamide de formule générale (I) :telle que définie dans les revendications, et leurs sels d'addition pharmaceutiquement acceptables.Elle concerne également leur procédé de préparation, les compositions pharmaceutiques les contenant, et leur utilisation en tant que substance pharmacologiquement active, notamment dans le traitement des neurodégénérescences, des maladies cardiovasculaires, inflammatoires et des hypercholestérolémies.
FR0404958A 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr Expired - Fee Related FR2869904B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0404958A FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr
CNA2005800146178A CN1950340A (zh) 2004-05-07 2005-05-09 Lxr受体调节剂
CA002564642A CA2564642A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr
AU2005251979A AU2005251979B2 (en) 2004-05-07 2005-05-09 LXR receptor modulators
EP05769960A EP1742918A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr
CN2011102511968A CN102321020A (zh) 2004-05-07 2005-05-09 Lxr受体调节剂
JP2007512270A JP4892475B2 (ja) 2004-05-07 2005-05-09 Ｌｘｒ受容体モジュレーター
PCT/FR2005/001139 WO2005121093A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr
US11/593,474 US7872021B2 (en) 2004-05-07 2006-11-07 LXR receptor modulators
NO20065501A NO20065501L (no) 2004-05-07 2006-11-29 Lxr reseptor modulstorer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0404958A FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr

Publications (2)

Publication Number Publication Date
FR2869904A1 true FR2869904A1 (fr) 2005-11-11
FR2869904B1 FR2869904B1 (fr) 2006-07-28

Family

ID=34945760

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0404958A Expired - Fee Related FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr

Country Status (9)

Country Link
US (1) US7872021B2 (fr)
EP (1) EP1742918A1 (fr)
JP (1) JP4892475B2 (fr)
CN (2) CN1950340A (fr)
AU (1) AU2005251979B2 (fr)
CA (1) CA2564642A1 (fr)
FR (1) FR2869904B1 (fr)
NO (1) NO20065501L (fr)
WO (1) WO2005121093A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071442A2 (fr) * 2005-12-22 2007-06-28 Novartis Ag Inhibiteurs d'activite du recepteur ccr9

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
EP2188266B1 (fr) * 2007-08-13 2012-10-17 F. Hoffmann-La Roche AG Nouveaux dérivés d'amides de la pipérazine
US8039493B2 (en) * 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017007755A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
WO2017223514A1 (fr) * 2016-06-24 2017-12-28 Saint Louis University Agonistes inverses de lxr pour le traitement du cancer
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
WO2019032528A1 (fr) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc Inhibiteurs bicycliques d'histone désacétylase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
US20030008861A1 (en) * 2001-03-20 2003-01-09 Lin Linus S. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053817A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Acide biarylalcanoique utilise en tant qu'inhibiteur de l'adhesion cellulaire
CN1265669A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla－4介导的白细胞粘着的化合物
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
DE69824037T2 (de) * 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6251932B1 (en) * 1998-09-25 2001-06-26 Asta Medica Ag Immunophilin ligands
US6300341B1 (en) * 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
JP2005022976A (ja) * 2001-07-18 2005-01-27 Ajinomoto Co Inc カルボン酸誘導体
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
ES2337037T3 (es) 2002-03-27 2010-04-20 Glaxosmithkline Llc Ciertos heterociclos aminoalquilicos sustituidos farmaceuticamente utiles.
US7560586B2 (en) 2002-03-27 2009-07-14 Smithkline Beecham Corporation Acid and ester compounds and methods of using the same
WO2003090869A1 (fr) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Modulateurs de lxr
WO2003090746A1 (fr) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles utilises en tant que modulateurs du lxr pour le traitement de maladies cardiovasculaires
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
CA2567343A1 (fr) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-cycliques de gamma-secretase
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
US20030008861A1 (en) * 2001-03-20 2003-01-09 Lin Linus S. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071442A2 (fr) * 2005-12-22 2007-06-28 Novartis Ag Inhibiteurs d'activite du recepteur ccr9
WO2007071442A3 (fr) * 2005-12-22 2007-08-16 Novartis Ag Inhibiteurs d'activite du recepteur ccr9
US7781481B2 (en) 2005-12-22 2010-08-24 Novartis Ag N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors

Also Published As

Publication number Publication date
WO2005121093A1 (fr) 2005-12-22
AU2005251979B2 (en) 2012-04-12
JP4892475B2 (ja) 2012-03-07
EP1742918A1 (fr) 2007-01-17
CA2564642A1 (fr) 2005-12-22
FR2869904B1 (fr) 2006-07-28
US7872021B2 (en) 2011-01-18
JP2007536355A (ja) 2007-12-13
AU2005251979A1 (en) 2005-12-22
CN1950340A (zh) 2007-04-18
NO20065501L (no) 2007-01-30
US20070099960A1 (en) 2007-05-03
CN102321020A (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA29926B1 (fr) Derives de pyrazine
TNSN07022A1 (fr) Derives de pyridine
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
TN2009000138A1 (fr) Biaryl-ether-urees
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
TN2009000544A1 (fr) Derives de benzimidazole
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA31894B1 (fr) Composes organiques
MA38138A1 (fr) Dérivés inédits de quinolone
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TN2009000450A1 (fr) Derives de pyridine
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140131